Table 1. Demographic and clinical manifestation of 264 participants (BC and HCs).
| Variables | Screening stage (n=40) | Training stage (n=60) | Validation stage (n=164) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BC | HC | P value | BC | HC | P value | BC | HC | P value | |||
| Total number | 25 | 15 | 30 | 30 | 82 | 82 | |||||
| Age years, mean ± SD | 62.2±12.6 | 64.9±5.5 | 0.45 | 63.7±13.5 | 65.5 ±13.2 | 0.60 | 61.2±13.5 | 62.7±9.1 | 0.41 | ||
| Gender, n (%) | 0.87 | 0.61 | 0.76 | ||||||||
| Male | 14 (56.0) | 8 (53.3) | 18 (60.0) | 16 (53.3) | 42 (51.2) | 44 (53.7) | |||||
| Female | 11 (44.0) | 7 (46.7) | 12 (56.7) | 14 (46.7) | 40 (47.8) | 38 (46.3) | |||||
| Histological grade, n (%) | |||||||||||
| Low | 12 (48.0) | 20 (66.7) | 43 (52.4) | ||||||||
| High | 13 (52.0) | 10 (33.3) | 39 (47.6) | ||||||||
Among three stages, there was no significant difference between BC and HCs in age and gender. Parameters were shown as number (percentage). Statistical contrast was exerted through the Kruskal-Wallis rank test. BC, bladder cancer; HC, healthy control.